Poniard Pharmaceuticals, Inc.
7000 Shoreline Court
Suite 270
South San Francisco
California
94080
United States
Tel: 650-583-3774
Fax: 650-583-3789
Website: http://www.poniard.com/
About Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors.
For additional information, please visit www.poniard.com.
171 articles about Poniard Pharmaceuticals, Inc.
-
Allozyme Cuts Workforce After Scrapping Merger Plan With Poniard Pharmaceuticals, Inc.; Poniard CEO, 4 Board Members Resign, Company Booted Off Nasdaq
1/4/2012
-
Poniard Pharmaceuticals, Inc. and Allozyme Terminate Planned Merger
12/22/2011
-
Poniard Pharmaceuticals, Inc. Announces Shareholders Approve Merger With Allozyne, Inc.
11/22/2011
-
Poniard Pharmaceuticals, Inc. Announces Licensing Agreement for Focal Adhesion Kinase Technology
11/18/2011
-
Poniard Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
10/31/2011
-
Poniard Pharmaceuticals, Inc. Announces Effectiveness of Form S-4 Registration Statement for the Proposed Merger with Allozyne, Inc.
10/10/2011
-
Poniard Pharmaceuticals, Inc. Receives Favorable NASDAQ Decision for Continued Listing of Company Shares
9/6/2011
-
Poniard Pharmaceuticals, Inc. Reports Second Quarter 2011 Financial Results
8/15/2011
-
Poniard Pharmaceuticals, Inc. Announces Filing of Form S-4 Registration Statement Related to Proposed Merger With Allozyne, Inc.
7/26/2011
-
Poniard Pharmaceuticals, Inc. Adjourns Reconvened Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal
7/12/2011
-
Poniard Pharmaceuticals, Inc. Announces Intention to Adjourn Annual Meeting of Shareholders to Solicit Additional Proxies for Important Reverse Stock Split Proposal
7/6/2011
-
Allozyne, Inc. Acquires Poniard Pharmaceuticals, Inc., Finds Backdoor Route to NASDAQ
6/23/2011
-
Poniard Pharmaceuticals, Inc. Adjourns Annual Meeting of Shareholders
6/10/2011
-
Poniard Pharmaceuticals, Inc. Board of Directors Urges Shareholders to Vote
6/1/2011
-
Poniard Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
5/13/2011
-
Poniard Pharmaceuticals, Inc. Announces It Will Seek Shareholder Approval of Reverse Stock Split at Annual Meeting
4/13/2011
-
Poniard Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2010 Financial Results
3/31/2011
-
Poniard Pharmaceuticals, Inc. Receives Chinese State SFDA Approval for Clinical Development of Picoplatin
3/1/2011
-
Poniard Pharmaceuticals, Inc. Completes $1.9 Million Financing
2/9/2011
-
Poniard Pharmaceuticals, Inc. Completes Voluntary Prepayment of Term Loans and Secures New Committed Equity Financing Facility
12/21/2010